ClinicalTrials.gg
Not yet recruitingNCT06860789Updated Mar 6, 2025

AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)

A Phase 1 interventional study of AK135 in Chemotherapy-induced Peripheral Neuropathy (CIPN), sponsored by Akeso. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-06.

Sponsored by Akeso · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
85
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AK135 for the treatment of chemotherapy-induced peripheral neuropathy in patients with malignant tumor

02

Conditions studied

  • Chemotherapy-induced Peripheral Neuropathy (CIPN)
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written and signed .
  2. (ECOG) Performance Score of 0 or 1.
  3. ≥ 3 months.
  4. or cytologically documented malignant tumor.
  5. Previous anti-tumor therapy causing peripheral neurotoxicity that has been discontinued for at least 1 month before enrollment.
  6. Diagnosed with Chemotherapy-Induced Peripheral Neuropathy (CIPN) by an oncologist or neurologist, with at least grade 2 NCI .
  7. Must have pain and/or numbness due to chemotherapy-induced peripheral neuropathy (CIPN) symptoms.
  8. Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. Pharmacologic or non-pharmacologic treatment for CIPN within 2 weeks before the first dose of AK135.
  2. Concurrent and/or scheduled to start any anti-tumor treatment that may cause Chemotherapy-Induced Peripheral Neuropathy (CIPN) within 3 months after the first dose of AK135.
  3. Concurrent and/or scheduled to start any anti-tumor treatment that may cause hand-foot skin reaction within 3 months after the first dose of AK135.
  4. Presence with other illnesses may result in peripheral neuropathy including, diseases, diabetes and metabolic syndrome, peripheral vascular disease, infections, nerve injury or compression, vitamin deficiencies, and so on.
  5. Skin lesions may affect the assessment of peripheral neuropathy.
  6. Unresolved toxicities from prior anti-cancer therapy within 2 weeks before the first dose of AK135, defined as not having resolved to v5.0 Grade 0 or 1, or levels specified in the inclusion/exclusion criteria, except for alopecia, and neuropathy.
  7. Known allergy or reaction to any component of the AK135 formulation. History of severe reactions to other mAbs.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
85 participants (estimated)

Study arms

  • Experimental
    AK135

    Each subject will receive a single dose of AK135 every 2-week cycle (Q2W) or every 1-week cycle (QW) or every 3-week cycle (Q3W).

    Drug: AK135

Interventions

  • DrugAK135

    IV infusion, specified dose with specified treatment frequency

06

What researchers measure

Primary outcomes

  1. Adverse events

    Incidence and severity of participants with adverse events

    Time frame: From time ICF is signed until 90 days after last dose of AK135

  2. DLT

    Time frame: During the first treatment cycle of AK135 (14 days)

Secondary outcomes

  1. EORTC-QLQ-CIPN20

    Patient-assessed European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale

    Time frame: through study completion, an average of 12 weeks

  2. BPI-SF

    Patient-assessed Brief Pain Inventory-Short Form

    Time frame: through study completion, an average of 12 weeks

  3. CTCAE-Neuropathy

    Physician-assessed Common Terminology Criteria for Adverse Events-Neurotoxicity

    Time frame: through study completion, an average of 12 weeks

  4. Cmax of AK135

    Time frame: through study completion, an average of 12 weeks

  5. AUC

    Time frame: through study completion, an average of 12 weeks

  6. t1/2

    Time frame: through study completion, an average of 12 weeks

  7. ADAs

    Number of subjects who develop detectable anti-drug antibodies

    Time frame: From first dose of study drug through 30 days after last dose of study drug.

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2025; primary completion for Mar 2026, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Mar 6, 2025
StartEst.
Feb 28, 2025
Primary completionEst.
Mar 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Mar 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06860789
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Mar 6, 2025
Start date
Feb 28, 2025 (estimated)
Primary completion
Mar 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 6, 2025

Study contacts

Xufang Yu
Contact
clinicaltrials@akesobio.com
+86(0760)8987399

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion